This article is more than 5 years old. Information may no longer be current.

FDA clears epithelial thickness mapping application for Cirrus HD-OCT

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has issued 510(k) clearance for the epithelial thickness mapping application for the Cirrus HD-OCT platform, Carl Zeiss Meditec announced in a press release.

The mapping capability expands the anterior segment capabilities of the platform, allowing for assessment before refractive surgery, monitoring of response to treatment and management of ocular surface disorders and progressive corneal diseases.

The epithelial thickness mapping application is a quick non-contact exam that takes less than 1 second, the release said.

“The addition of this new software is another testament of our continued commitment to providing our customers innovative platforms,” James V. Mazzo, global president of ophthalmic devices at Carl Zeiss Meditec, said in the release.